Product development in the life sciences sector is frequently complex, costly, and time-consuming, and collaborations between companies are common. Disputes may arise at all stages of development and commercialization. Our experience helps clients navigate disputes involving drug development and commercialization and identify relevant commercial factors (size of the opportunity, therapeutic area, business risks, etc.). CRA has provided expert reports and testimony evaluating development and commercialization efforts and assessing damages associated with alleged contractual breaches.
Engagements
- 01Breach of contract damages analysis and testimonyCRA developed economic analyses to determine damages in a breach of contract case related to microarray technology. CRA prepared a preliminary damages report...View engagement
- 02CRA assesses pharmaceutical supply agreements for potential competitive benefitsA manufacturer of a Schedule II product entered into sequential patent settlement agreements that included product supply agreements. Following allegations...View engagement
- 03CRA evaluates commercial efforts to develop a MS drug with respect contractual obligations following mergerCRA assessed commercial efforts to develop and commercialize a MS drug with respect to obligations stemming from the acquisition of Genzyme Corporation by...View engagement